Jonathan Sronin, Chief medicine (TASE:) Executives at Pacira Biosciences, Inc. (NASDAQ: PCRX), a healthcare company with a market capitalization of $858 million and an InvestingPro Financial Health Score of Excellent, recently sold 879 shares of the company’s common stock. . The transaction closed on January 6, 2025, at $18.40 per share, for a total price of $16,173. The sale was conducted pursuant to a Rule 10b5-1 trading plan previously employed by Slonin. InvestingPro’s analysis shows the stock is undervalued based on fair value valuations, with five analysts recently raising their earnings estimates.
Additionally, on January 2, 2025, Slonin disposed of 371 shares at a price of $18.33 per share to cover tax obligations related to the vesting of restricted stock units. Following these transactions, Sronin will now own 93,443.511 shares of Pasira Biosciences. This includes shares acquired through the company’s employee stock purchase plan in December 2024. For deeper insights into insider trading patterns and a comprehensive analysis including 8 additional Pro Tips, read the full Pro Research report. Available at InvestingPro.
In other recent news, Pacira BioSciences, Inc. reported significant developments in non-opioid pain management solutions. The company’s gene therapy candidate, PCRX-201, demonstrated sustained improvements in knee pain, stiffness, and function for up to 104 weeks in patients with moderate to severe osteoarthritis in a Phase 1 trial. This progress will be presented at the American College of Rheumatology’s annual meeting.
On the financial front, Pacira’s Q3 2024 results saw EXPAREL sales increase from $128.7 million to $132 million. The company reported non-GAAP gross margins of 78% and adjusted EBITDA of $54.7 million. Despite ZILRETTA’s challenges, the company maintained its 2024 revenue outlook of $680 million to $705 million and adjusted gross margin of 74% to 76%.
In its earnings release, Pacira emphasized its strategic focus on patient care and non-opioid pain therapies as it aims to accelerate growth in 2025. The company also highlighted the upcoming implementation of the NOPAIN reimbursement policy, which is expected to improve access to EXPAREL. These recent developments strengthen Pasira’s continued commitment to providing innovative pain management solutions.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
